Perbandingan Penggunaan Efavirenz dan Nevirapine Terhadap Kolesterol LDL Pasien HIV/AIDS

• Main Authors: Anggriani Yusi (Author), Evy Yunihastuti (Author), Yulia Trisna (Author), Ade Rosanti (Author), Reise Manninda (Author), Rifka Annisa (Author)
• Format: Book
• Published: Universitas Indonesia, 2019-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: https://doi.org/10.7454/psr.v6i2.4225; 2407-2354; 2477-0612
• Keywords: hiv/aids; efavirenz; nevirapine; ldl cholesterol; Pharmacy and materia medica; RS1-441; Therapeutics. Pharmacology; RM1-950
• Source: Pharmaceutical Sciences and Research, Vol 6, Iss 2, Pp 118-123 (2019)

Gangguan metabolik lipid merupakan kondisi yang sering ditemukan pada pasien HIV (Human Immunodeficiency Virus)/AIDS (Acquired Immuno Deficiency Syndrome) pada pasien yang menggunakan antiretroviral (ARV) lini pertama seperti efavirenz dan nevirapine. Penelitian ini bertujuan untuk membandingkan kolesterol LDL pasien HIV/AIDS pasien yang menggunakan efavirenz dan nevirapine. Penelitian dilakukan secara prospektif selama 2 bulan. Responden penelitian adalah pasien yang menggunakan ARV lini pertama minimal selama enam bulan, berusia ≥18 tahun, bukan wanita hamil, tidak mengidap infeksi oportunistik mycobacterium ovium complex, dan tidak mengkonsumsi antihiperlipidemia, kortikosteroid, retinoid selama 3 bulan terakhir. Jumlah pasien yang digunakan sebanyak 70 orang dan dibagi menjadi dua kelompok. Analisa ststistik T independent digunakan untuk membandingkan kolesterol LDL antara kelompok efavirenz dan neverapine. Kelompok efavirenz memiliki rata-rata kolesterol LDL sebesar 142,31 mg/dL ±41,461, sedangkan nevirapine 126,83 mg/dL ±40,55. Studi menunjukkan pasien yang menggunakan efavirenz memiliki kolesterol LDL lebih tinggi dibandingkan nevirapin namun tidak bermakna secara statistik. Lipid metabolism disorder is one of common condition among HIV (Human Immunodeficiency Virus)/AIDS (Acquired Immune Deficiency Syndrome) patients who used first line antiretroviral efavirenz and nevirapine. This study was conducted to compare LDL (Low Density Lipoprotein) cholesterol between two group HIV/AIDS patients with efavirenz and nevirapine. The prospective study was performed in 2 months. HIV/AIDS patients who used first line antiretroviral at least for 6 months, aged ≥18 years old, not pregnant, without Mycobacterium ovium complex opportunistic infection and antihyperlipidemic, corticosteroid, retinoid in last 3 months were included. The 70 patients who enrolled in this study were divided into two groups. The independent T test was carried out to analyze the different of LDL cholesterol between two group. The group of patients using efavirenz showed 142.31 ±41,461 mg/dL and the group of nevirapine 126.83 ±40,55 mg/dL LDL cholesterol. This study showed that patient with efavirenze had higher LDL than nevirapine, but not statistically different.